Patents by Inventor Michael David Bentley

Michael David Bentley has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9333200
    Abstract: Provided herein are water-soluble prodrugs, compositions comprising such prodrugs, and related methods of making and administering the same. The prodrugs of the invention comprise a water-soluble polymer having three or more arms, at least three of which are typically covalently attached to an active agent, e.g., a small molecule. The conjugates of the invention provide an optimal balance of polymer size and structure for achieving improved drug loading, since the conjugates of the invention possess three or more active agents releasably attached to a multi-armed water-soluble polymer. The prodrugs of the invention are therapeutically effective, and exhibit improved properties in-vivo when compared to unmodified parent drug.
    Type: Grant
    Filed: July 3, 2014
    Date of Patent: May 10, 2016
    Assignee: Nektar Therapeutics
    Inventors: Xuan Zhao, Michael David Bentley, Zhongxu Ren, Tacey X. Viegas
  • Patent number: 9169354
    Abstract: The present disclosure provides copolymers of 2-substituted-2-oxazolines possessing two or three reactive functional groups which are also chemically orthogonal. The copolymers described may be random copolymers, block copolymers or a mixture of random and block copolymer configurations. Furthermore, the present disclosure provides novel methods for synthesizing the above polymers and for conjugating to molecules such as targeting, diagnostic and therapeutic agents.
    Type: Grant
    Filed: February 6, 2012
    Date of Patent: October 27, 2015
    Assignee: Serina Therapeutics, Inc.
    Inventors: Kunsang Yoon, J. Milton Harris, Michael David Bentley
  • Publication number: 20150273074
    Abstract: The present disclosure provides copolymers of 2-substituted-2-oxazolines possessing two or three reactive functional groups which are also chemically orthogonal. The copolymers described may be random copolymers, block copolymers or a mixture of random and block copolymer configurations. Furthermore, the present disclosure provides novel methods for synthesizing the above polymers find for conjugating to molecules such as targeting, diagnostic and therapeutic agents.
    Type: Application
    Filed: February 20, 2015
    Publication date: October 1, 2015
    Inventors: J. Milton HARRIS, Kunsang YOON, Michael David BENTLEY, Zhihao FANG, Tacey VIEGAS
  • Publication number: 20150190526
    Abstract: The present disclosure provides POZ derivatives having a range of active functional groups allowing conjugation of POZ derivatives to a variety of target molecules under a wide range of reaction conditions to produce a hydrolytically stable target molecule-POZ conjugate. Furthermore, the present disclosure provides novel methods of synthesis for the disclosed POZ derivatives and hydrolytically stable target molecule-POZ conjugates created using the disclosed terminally activated monofunctional POZ derivatives. In one embodiment, the POZ derivative is a terminally activated monofunctional POZ derivative.
    Type: Application
    Filed: March 20, 2015
    Publication date: July 9, 2015
    Inventors: J. Milton HARRIS, Michael David Bentley, Kunsang Yoon, Zhihao Fang, Francesco Maria Veronese, Tacey Viegas, Anna Mero
  • Publication number: 20150079658
    Abstract: The present disclosure provides POZ derivatives having a range of active functional groups allowing conjugation of POZ derivatives to a variety of target molecules under a wide range of reaction conditions to produce a hydrolytically stable target molecule-POZ conjugate. Furthermore, the present disclosure provides novel methods of synthesis for the disclosed POZ derivatives and hydrolytically stable target molecule-POZ conjugates created using the disclosed terminally activated monofunctional POZ derivatives. In one embodiment, the POZ derivative is a terminally activated monofunctional POZ derivative.
    Type: Application
    Filed: November 21, 2014
    Publication date: March 19, 2015
    Inventors: J Milton HARRIS, Michael David Bentley, Kunsang Yoon, Zhihao Fang, Francesco Maria Veronese, Tacey Viegas, Anna Mero
  • Patent number: 8883211
    Abstract: The present disclosure provides novel functional polyoxazoline derivatives prepared by terminating polyoxazoline polymerization with inert chemical groups. In addition, the present disclosure demonstrates the synthesis of novel electrophilic initiators with protected functional groups capable of initiating oxazoline polymerization and capable of surviving the conditions of polymerization. These initiators are used to synthesize the above inert-terminal polyoxazoline derivatives as well as other polyoxazolines with active terminal groups. Furthermore, the present disclosure provides for polyoxazoline-lipid conjugates and liposomal compositions prepared using such polyoxazoline-lipid conjugates. Methods of using the foregoing to prepare conjugates with target molecules are also disclosed.
    Type: Grant
    Filed: July 10, 2009
    Date of Patent: November 11, 2014
    Assignee: Serina Therapeutics, Inc.
    Inventors: Michael David Bentley, J. Milton Harris, Michael Reif, Rainer Jordon, Kunsang Yoon
  • Publication number: 20140323514
    Abstract: Provided herein are water-soluble prodrugs, compositions comprising such prodrugs, and related methods of making and administering the same. The prodrugs of the invention comprise a water-soluble polymer having three or more arms, at least three of which are typically covalently attached to an active agent, e.g., a small molecule. The conjugates of the invention provide an optimal balance of polymer size and structure for achieving improved drug loading, since the conjugates of the invention possess three or more active agents releasably attached to a multi-armed water-soluble polymer. The prodrugs of the invention are therapeutically effective, and exhibit improved properties in-vivo when compared to unmodified parent drug.
    Type: Application
    Filed: July 3, 2014
    Publication date: October 30, 2014
    Inventors: Xuan Zhao, Michael David Bentley, Zhongxu Ren, Tacey X. Viegas
  • Publication number: 20140271527
    Abstract: The present disclosure provides polymer conjugates comprising a polymer and an agent, the agent linked to the polymer via a linking group containing a cleavable moiety.
    Type: Application
    Filed: November 1, 2012
    Publication date: September 18, 2014
    Applicant: Serina Therapeutics, Inc.
    Inventors: Randall Moreadith, Kunsang Yoon, Zhihao Fang, Rebecca Weimer, Bekir Dizman, Tacey Viegas, Michael David Bentley
  • Patent number: 8809453
    Abstract: The present invention is directed to branched reactive water-soluble polymers comprising at least two polymer arms, such as poly(ethylene glycol), attached to a central aliphatic hydrocarbon core molecule through heteroatom linkages. The branched polymers bear at least one functional group for reacting with a biologically active agent to form a biologically active conjugate. The functional group of the branched polymer can be directly attached to the aliphatic hydrocarbon core or via an intervening linkage, such as a heteroatom, -alkylene-, —O-alkylene-O—, -alkylene-O-alkylene-, -aryl-O—, —O-aryl-, (—O-alkylene-)m, or (-alkylene-O—)m linkage, wherein m is 1-10.
    Type: Grant
    Filed: April 18, 2013
    Date of Patent: August 19, 2014
    Assignee: Nektar Therapeutics
    Inventors: Michael David Bentley, Xuan Zhao, Xiaoming Shen, William Dudley Battle, III
  • Patent number: 8771662
    Abstract: Provided herein are water-soluble prodrugs, compositions comprising such prodrugs, and related methods of making and administering the same. The prodrugs of the invention comprise a water-soluble polymer having three or more arms, at least three of which are typically covalently attached to an active agent, e.g., a small molecule. The conjugates of the invention provide an optimal balance of polymer size and structure for achieving improved drug loading, since the conjugates of the invention possess three or more active agents releasably attached to a multi-armed water-soluble polymer. The prodrugs of the invention are therapeutically effective, and exhibit improved properties in-vivo when compared to unmodified parent drug.
    Type: Grant
    Filed: February 12, 2013
    Date of Patent: July 8, 2014
    Assignee: Nektar Therapeutics
    Inventors: Xuan Zhao, Michael David Bentley, Zhongxu Ren, Tacey X. Viegas
  • Publication number: 20140112880
    Abstract: The present disclosure provides polymer conjugates comprising a polymer and an agent, the agent linked to the polymer via a linking group containing a hydrolyzable moiety.
    Type: Application
    Filed: December 2, 2013
    Publication date: April 24, 2014
    Applicant: Serina Therapeutics, Inc.
    Inventors: Randall MOREADITH, Michael David Bentley, Kunsang Yoon, Zhihao Fang, Rebecca Welmer, Bekir Dizman, Tacey Viegas
  • Publication number: 20140066577
    Abstract: The present disclosure provides copolymers of 2-substituted-2-oxazolines possessing two or three reactive functional groups which are also chemically orthogonal. The copolymers described may be random copolymers, block copolymers or a mixture of random and block copolymer configurations. Furthermore, the present disclosure provides novel methods for synthesizing the above polymers and for conjugating to molecules such as targeting, diagnostic and therapeutic agents.
    Type: Application
    Filed: August 2, 2013
    Publication date: March 6, 2014
    Applicant: Serina Therapeutics, Inc.
    Inventors: Kunsang YOON, J. Milton HARRIS, Michael David BENTLEY, Zhihac FANG, Tacey VIEGAS
  • Publication number: 20140011964
    Abstract: The present disclosure provides POZ derivatives having a range of active functional groups allowing conjugation of POZ derivatives to a variety of target molecules under a wide range of reaction conditions to produce a hydrolytically stable target molecule-POZ conjugate. Furthermore, the present disclosure provides novel methods of synthesis for the disclosed POZ derivatives and hydrolytically stable target molecule-POZ conjugates created using the disclosed terminally activated monofunctional POZ derivatives. In one embodiment, the POZ derivative is a terminally activated monofunctional POZ derivative.
    Type: Application
    Filed: August 7, 2013
    Publication date: January 9, 2014
    Applicant: Serina Therapeutics, Inc.
    Inventors: J. Milton HARRIS, Michael David Bentley, Kunsang Yoon, Zhihao Fang, Francesco Maria Veronese, Tacey Viegas, Anna Mero
  • Patent number: 8617530
    Abstract: The invention provides polymer conjugates of opioid antagonists comprising a polymer, such as poly(ethylene glycol), covalently attached to an opioid antagonist. The linkage between the polymer and the opioid antagonist is preferably hydrolytically stable. The invention also includes a method of treating one or more side effects associated with the use of opioid analgesics, such as constipation, nausea, or pruritus, by administering a polymer conjugate of the invention.
    Type: Grant
    Filed: November 29, 2012
    Date of Patent: December 31, 2013
    Assignee: Nektar Therapeutics
    Inventors: Michael James Roberts, Xiaoming Shen, Lin Cheng, Michael David Bentley
  • Patent number: 8597633
    Abstract: The present disclosure provides polymer conjugates comprising a polymer and an agent, the agent linked to the polymer via a linking group containing a hydrolyzable moiety.
    Type: Grant
    Filed: February 22, 2013
    Date of Patent: December 3, 2013
    Assignee: Serina Therapeutics, inc.
    Inventors: Randall Moreadith, Michael David Bentley, Kunsang Yoon, Zhihao Fang, Rebecca Weimer, Bekir Dizman, Tacey Viegas
  • Publication number: 20130295639
    Abstract: The present invention is directed to branched reactive water-soluble polymers comprising at least two polymer arms, such as poly(ethylene glycol), attached to a central aliphatic hydrocarbon core molecule through heteroatom linkages. The branched polymers bear at least one functional group for reacting with a biologically active agent to form a biologically active conjugate. The functional group of the branched polymer can be directly attached to the aliphatic hydrocarbon core or via an intervening linkage, such as a heteroatom, -alkylene-, —O-alkylene-O—, -alkylene-O-alkylene-, -aryl-O—, —O-aryl-, (—O-alkylene-)m, or (-alkylene-O—)m linkage, wherein m is 1-10.
    Type: Application
    Filed: April 18, 2013
    Publication date: November 7, 2013
    Inventors: Michael David Bentley, Xuan Zhao, Xiaoming Shen, William Dudley Battle, III
  • Patent number: 8501899
    Abstract: The present disclosure provides copolymers of 2-substituted-2-oxazolines possessing two or three reactive functional groups which are also chemically orthogonal. The copolymers described may be random copolymers, block copolymers or a mixture of random and block copolymer configurations. Furthermore, the present disclosure provides novel methods for synthesizing the above polymers and for conjugating to molecules such as targeting, diagnostic and therapeutic agents.
    Type: Grant
    Filed: January 23, 2012
    Date of Patent: August 6, 2013
    Assignee: Serina Therapeutics, Inc.
    Inventors: Kunsang Yoon, J. Milton Harris, Michael David Bentley, Zhihao Fang, Tacey Viegas
  • Patent number: 8440623
    Abstract: A substantially hydrophilic conjugate is provided having a peptide that is capable of passing the blood-brain barrier covalently linked to a water-soluble nonpeptidic polymer such as polyethylene glycol. The conjugate exhibits improved solubility and in vivo stability and is capable of passing the blood-brain barrier of an animal.
    Type: Grant
    Filed: June 28, 2011
    Date of Patent: May 14, 2013
    Assignee: Nektar Therapeutics
    Inventors: Michael David Bentley, Michael James Roberts
  • Patent number: 8440816
    Abstract: The present invention is directed to branched reactive water-soluble polymers comprising at least two polymer arms, such as poly(ethylene glycol), attached to a central aliphatic hydrocarbon core molecule through ether linkages. The branched polymers bear at least one functional group for reacting with a biologically active agent to form a biologically active conjugate. The functional group of the branched polymer can be directly attached to the aliphatic hydrocarbon core or via an intervening linkage, such as a heteroatom, -alkylene-, —O-alkylene-O—, -alkylene-O-alkylene-, -aryl-O—, —O-aryl-, (—O-alkylene-)m, or (-alkylene-O—)m linkage, wherein m is 1-10.
    Type: Grant
    Filed: August 24, 2012
    Date of Patent: May 14, 2013
    Assignee: Nektar Therapeutics
    Inventors: Michael David Bentley, Xuan Zhao, Xiaoming Shen, William Dudley Battle, III
  • Patent number: 8394365
    Abstract: Provided herein are water-soluble prodrugs, compositions comprising such prodrugs, and related methods of making and administering the same. The prodrugs of the invention comprise a water-soluble polymer having three or more arms, at least three of which are typically covalently attached to an active agent, e.g., a small molecule. The conjugates of the invention provide an optimal balance of polymer size and structure for achieving improved drug loading, since the conjugates of the invention possess three or more active agents releasably attached to a multi-armed water-soluble polymer. The prodrugs of the invention are therapeutically effective, and exhibit improved properties in-vivo when compared to unmodified parent drug.
    Type: Grant
    Filed: November 30, 2007
    Date of Patent: March 12, 2013
    Assignee: Nektar Therapeutics
    Inventors: Xuan Zhao, Michael David Bentley, Zhongxu Ren, Tacey X. Viegas